| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
32,057 |
26,464 |
$6.50M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
18,571 |
14,362 |
$4.15M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,729 |
2,751 |
$1.41M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
7,778 |
6,661 |
$1.36M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,744 |
2,205 |
$964K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,377 |
2,557 |
$561K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
10,537 |
7,937 |
$395K |
| G0378 |
Hospital observation service, per hour |
2,127 |
969 |
$359K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,656 |
1,346 |
$250K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,308 |
6,655 |
$198K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
4,428 |
3,203 |
$159K |
| 80053 |
Comprehensive metabolic panel |
24,057 |
17,608 |
$157K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,156 |
3,328 |
$131K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
673 |
210 |
$122K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
695 |
514 |
$114K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
550 |
419 |
$103K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
347 |
258 |
$96K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
923 |
752 |
$95K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,068 |
3,068 |
$92K |
| 85027 |
|
31,589 |
21,976 |
$89K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
3,025 |
996 |
$83K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,416 |
1,785 |
$81K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
3,629 |
2,475 |
$80K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
53 |
39 |
$74K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,235 |
1,380 |
$72K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
748 |
634 |
$68K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
4,506 |
1,044 |
$66K |
| 71046 |
Radiologic examination, chest; 2 views |
4,719 |
3,802 |
$48K |
| 84443 |
Thyroid stimulating hormone (TSH) |
5,392 |
4,251 |
$46K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
1,009 |
261 |
$40K |
| 71045 |
Radiologic examination, chest; single view |
4,593 |
3,357 |
$38K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,094 |
786 |
$35K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
70 |
48 |
$32K |
| 97535 |
Self-care/home management training, each 15 minutes |
1,815 |
523 |
$29K |
| 84484 |
|
6,567 |
4,111 |
$27K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,045 |
1,743 |
$27K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
267 |
223 |
$26K |
| 93971 |
|
258 |
209 |
$25K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,000 |
823 |
$24K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,235 |
3,102 |
$19K |
| 97163 |
|
756 |
521 |
$19K |
| 73630 |
|
484 |
423 |
$17K |
| 80061 |
Lipid panel |
2,127 |
1,795 |
$17K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,538 |
908 |
$16K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,746 |
3,628 |
$16K |
| A0425 |
Ground mileage, per statute mile |
332 |
294 |
$16K |
| 73610 |
|
436 |
364 |
$15K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
24 |
16 |
$14K |
| 83690 |
|
4,724 |
3,579 |
$14K |
| 84703 |
|
2,736 |
2,188 |
$14K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
3,965 |
2,679 |
$13K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
85 |
67 |
$13K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,142 |
1,645 |
$13K |
| 83735 |
|
4,536 |
2,894 |
$12K |
| 81025 |
|
2,919 |
2,429 |
$11K |
| 76830 |
Ultrasound, transvaginal |
176 |
145 |
$11K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
394 |
230 |
$11K |
| 82077 |
|
1,665 |
1,234 |
$10K |
| 83605 |
|
2,420 |
1,619 |
$10K |
| 80076 |
|
2,496 |
1,748 |
$10K |
| 87040 |
|
1,862 |
1,030 |
$10K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
593 |
494 |
$10K |
| 73130 |
|
279 |
238 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,787 |
1,448 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,567 |
1,387 |
$8K |
| 81003 |
|
7,042 |
5,467 |
$8K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
173 |
157 |
$8K |
| 83880 |
|
719 |
539 |
$8K |
| 97803 |
|
881 |
703 |
$8K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
494 |
429 |
$8K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
494 |
429 |
$8K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,254 |
1,761 |
$7K |
| 36415 |
Collection of venous blood by venipuncture |
8,824 |
6,551 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
8,724 |
6,285 |
$7K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
221 |
199 |
$7K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
4,867 |
3,455 |
$7K |
| 85610 |
|
4,793 |
3,304 |
$6K |
| 96376 |
|
311 |
220 |
$6K |
| 80047 |
|
2,243 |
1,532 |
$6K |
| 71250 |
|
37 |
26 |
$6K |
| 73030 |
|
189 |
150 |
$6K |
| 87081 |
|
1,477 |
1,301 |
$6K |
| 85379 |
|
1,313 |
1,022 |
$6K |
| 73562 |
|
341 |
285 |
$6K |
| 73110 |
|
158 |
133 |
$5K |
| 85730 |
|
2,525 |
1,778 |
$5K |
| 81001 |
|
4,496 |
3,580 |
$5K |
| 12001 |
|
27 |
26 |
$5K |
| 87186 |
|
1,142 |
859 |
$5K |
| 90715 |
|
161 |
146 |
$4K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
86 |
56 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
598 |
525 |
$4K |
| 82728 |
|
368 |
319 |
$3K |
| 72100 |
|
69 |
57 |
$3K |
| 87070 |
|
720 |
551 |
$3K |
| 82607 |
|
409 |
338 |
$3K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,065 |
1,335 |
$3K |
| 83550 |
|
567 |
471 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
224 |
204 |
$3K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,084 |
674 |
$3K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
14 |
12 |
$3K |
| 86140 |
|
889 |
679 |
$3K |
| 76775 |
|
43 |
38 |
$3K |
| ATP14 |
|
258 |
231 |
$3K |
| 84100 |
|
1,314 |
736 |
$2K |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,777 |
1,249 |
$2K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
241 |
65 |
$2K |
| 87077 |
|
668 |
511 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
101 |
95 |
$2K |
| 83540 |
|
589 |
488 |
$2K |
| A9270 |
Non-covered item or service |
10,762 |
2,361 |
$2K |
| J3490 |
Unclassified drugs |
1,276 |
890 |
$2K |
| 87147 |
|
741 |
591 |
$2K |
| 80179 |
|
256 |
198 |
$2K |
| 87205 |
|
745 |
573 |
$2K |
| 80143 |
|
278 |
213 |
$2K |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
928 |
780 |
$2K |
| 10060 |
|
13 |
12 |
$2K |
| 84439 |
|
313 |
245 |
$2K |
| 85652 |
|
993 |
750 |
$2K |
| 97162 |
|
34 |
27 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,578 |
1,077 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
893 |
648 |
$1K |
| C1769 |
Guide wire |
21 |
12 |
$1K |
| 84702 |
|
152 |
111 |
$1K |
| 87158 |
|
304 |
227 |
$1K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
26 |
12 |
$1K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,073 |
736 |
$1K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
897 |
593 |
$926.59 |
| 74018 |
|
102 |
78 |
$917.87 |
| 82746 |
|
100 |
78 |
$890.16 |
| J2060 |
Injection, lorazepam, 2 mg |
995 |
706 |
$884.52 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
16 |
12 |
$876.79 |
| 87631 |
|
33 |
27 |
$860.14 |
| 86850 |
|
169 |
132 |
$786.54 |
| 87807 |
|
128 |
104 |
$776.28 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
21 |
17 |
$764.19 |
| J1644 |
Injection, heparin sodium, per 1000 units |
435 |
181 |
$731.32 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
958 |
603 |
$625.25 |
| 86618 |
|
31 |
28 |
$549.01 |
| 86900 |
|
358 |
272 |
$526.37 |
| 86901 |
|
358 |
272 |
$494.69 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
799 |
621 |
$454.22 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
443 |
323 |
$428.00 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
128 |
112 |
$392.54 |
| 73502 |
|
15 |
13 |
$266.94 |
| J2704 |
Injection, propofol, 10 mg |
797 |
496 |
$260.34 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
59 |
54 |
$251.33 |
| 97035 |
|
34 |
12 |
$217.63 |
| 82570 |
|
51 |
44 |
$136.90 |
| 86803 |
|
13 |
12 |
$130.22 |
| 82150 |
|
30 |
26 |
$112.48 |
| 82330 |
|
43 |
27 |
$63.21 |
| 82248 |
|
38 |
25 |
$48.49 |
| 86308 |
|
12 |
12 |
$43.59 |
| 82565 |
|
34 |
24 |
$42.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
67 |
59 |
$40.24 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
16 |
12 |
$36.38 |
| 81015 |
|
15 |
14 |
$19.53 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
15 |
12 |
$12.97 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
17 |
14 |
$12.40 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
131 |
76 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
171 |
95 |
$0.00 |
| G1003 |
Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program |
193 |
153 |
$0.00 |
| G1011 |
Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program |
48 |
40 |
$0.00 |